Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q1 GAAP EPS of -$0.18. As of March 31, 2022, Corvus had cash, cash equivalents and marketable securities totaling $62.9 million For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.18
BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are adva...
BURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs...
Penny stocks are a great way to quickly make money in the stock market. Today we are looking at a handful that insiders including top management have decided to scoop up as the second quarter begins. The topic of stocks with insider activity has become a bigger point of focus for trader...
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2021 Earnings Conference Call March 10, 2022 04:30 PM ET Company Participants Richard Miller - Co-Founder, President and CEO Leiv Lea - CFO Zack Kubow - Investor Relations, Real Chemistry Conference Call Participants Li Watsek - Cantor Fitzgerald Mara Go...
Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q4 GAAP EPS of -$0.20 misses by $0.01. Q4 Cash and cash equivalents $69.45M For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01
BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. ...
BURLINGAME, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update ...
Gainers: Brookdale Senior Living BKD +16%. American Shared Hospital Services AMS +12%. ImmunityBio IBRX +12%. I-Mab (NASDAQ:IMAB) +11%. Corvus Pharmaceuticals (NASDAQ:CRVS) +9%. Losers: Larimar Therapeutics LRMR -65%. Omnicell (NASDAQ:OMCL) -18%. M...
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-o...
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforade...